The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Beyfortus



Sanofi Winthrop IndustrieEU/1/22/1689/004-006

Main Information

Trade NameBeyfortus
Active SubstancesNirsevimab
Dosage FormSolution for injection in pre-filled syringe
Licence HolderSanofi Winthrop Industrie
Licence NumberEU/1/22/1689/004-006

Group Information

ATC CodeJ06BD08 Nivsevimab

Status

License statusAuthorised
Licence Issued31/10/2022
Legal status*** AWAITING VALUE ***
Supply Status
Advertising Status*** AWAITING VALUE ***
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back